Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...
Meanwhile, hemophilia A drug Altuviiio reached nearly a quarter of a billion euros in sales in the fourth quarter, with Sanofi crediting that growth to an increasing number of patients switching ...
Hosted on MSN1mon
Sanofi Down 10% in 3 Months: How Should You Play the Stock?Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...
Among Sanofi’s rare disease drugs, its new rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €230 million in the fourth ...
The Sanofi Global Health Unit plays an important ... And the second question, a very short one, given the current dynamics with ALTUVIIIO, is that one your next blockbuster and no later than ...
Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher sales of Dupixent and contributions from new products like Altuviiio and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback